Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CRIS
Curis Inc
stock NASDAQ

Market Open
Aug 5, 2026 2:35:19 PM EDT
4.47USD-6.184%(-0.30)53,122
3.83Bid   5.26Ask   1.43Spread
Pre-market
Aug 3, 2026 9:04:30 AM EDT
5.20USD+0.971%(+0.05)0
After-hours
Aug 4, 2026 4:25:30 PM EDT
4.72USD-1.048%(-0.05)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
08:01AM EST  Curis to Present at Upcoming Healthcare Conferences   PR Newswire
Jan 7, 2022
04:01PM EST  Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)   PR Newswire
01:08PM EST  Watching Curis; Hearing B Riley Sets Buy Rating, $22 Price Target   Benzinga
Jan 6, 2022
10:59AM EST  Curis Shares Down 27%   RTTNews
10:16AM EST  Mid-Morning Market Update: Markets Open Lower; Walgreens Tops Q1 Views   Benzinga
07:07AM EST  Curis Announces Updated Data With Additional Encouraging Clinical Activity In Phase 1/2 Study Of CA-4948 Monotherapy In Targeted Patients With Relapsed Or Refractory AML And MDS   Benzinga
07:05AM EST  Curis Reports Data With Addl Clinical Activity In Phase 1/2 Study Of CA-4948 Monotherapy In Relapsed/Refractory AML,MDS   RTTNews
07:01AM EST  Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors   PR Newswire
Jan 3, 2022
08:01AM EST  Curis Adds Three New Executives to Management Team Strengthening Medical   PR Newswire
07:01AM EST  Curis to Present at H.C. Wainwright BioConnect Conference   PR Newswire
Dec 15, 2021
08:02AM EST  Curis to be Added to the Nasdaq Biotechnology Index and the iShares   PR Newswire
Dec 6, 2021
08:01AM EST  Curis Appoints John A. Hohneker, M.D. To Board Of Directors   PR Newswire
Nov 9, 2021
05:08PM EST  Curis Q3 EPS $(0.12) Beats $(0.13) Estimate, Sales $3.04M Beat $2.79M Estimate   Benzinga
04:03PM EST  Curis Q4 Loss/share $0.12 Vs. Loss $0.11 Year Ago   RTTNews
04:01PM EST  Curis Reports Third Quarter 2021 Financial Results and Business Update   PR Newswire
11:42AM EST  Curis Announces To Present Preclinical Data For CI-8993 At Society For Immunotherapy Of Cancer (SITC) Annual Meeting   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
08:03AM EST  Curis Announces New Preclinical Data for CI-8993 at the Society for   PR Newswire
08:03AM EST  Curis Announces New Preclinical Data For CI-8993 At The Society For Immunotherapy Of Cancer   RTTNews
Nov 8, 2021
09:59AM EST  Curis Earnings Preview   Benzinga
08:05AM EST  Curis Announces First Patient Dosed In Phase 1/2 Study Of CA-4948 Combination Therapy In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndromes   Benzinga
08:05AM EST  Curis Says First Patient Dosed In Phase 1/2 Study Of CA-4948 In Patients With Refractory Acute Myeloid Leukemia   RTTNews
08:03AM EST  Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes   PR Newswire
Nov 4, 2021
11:14AM EDT  Watching Curis; Traders Circulate TipRanks Report 'Analysts Say These 2 Stocks Are Their Top Picks Into YE21' Mentioning Stock; Article Also Mentions Customers Bancorp   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 2, 2021
04:02PM EDT  Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call   PR Newswire
08:01AM EDT  Curis to Present at Upcoming Investor Conferences   PR Newswire
Oct 13, 2021
01:38PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2021   Benzinga
01:38PM EDT  Raymond James Initiates Coverage On Curis with Outperform Rating, Announces Price Target of $15   Benzinga
Oct 7, 2021
09:21AM EDT  Curis Announces New Preclinical Data Highlighting Potential Of CA-4948 In Multiple Hematologic Malignancies Presented At AACR-NCI-EORTC Virtual Conference   Benzinga
09:10AM EDT  Curis Presents Data Highlights Potential Of CA-4948 In Multiple Hematologic Malignancies On Molecular Targets   RTTNews
09:05AM EDT  Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics   PR Newswire
Oct 6, 2021
04:01PM EDT  Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)   PR Newswire
Sep 2, 2021
08:02AM EDT  Curis to Present at Upcoming Healthcare Conferences in September   PR Newswire
Aug 20, 2021
01:51PM EDT  Return on Capital Employed Overview: Curis   Benzinga
Aug 3, 2021
04:32PM EDT  Recap: Curis Q2 Earnings   Benzinga
04:07PM EDT  Curis Reports Q2 Loss Per Share Of $0.12 Vs. $0.17 Last Year   RTTNews
04:00PM EDT  Curis Q2 EPS $(0.12) Misses $(0.11) Estimate, Sales $2.29M Miss $2.48M Estimate   Benzinga
04:00PM EDT  Curis Reports Second Quarter 2021 Financial Results   PR Newswire
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Jul 27, 2021
04:01PM EDT  Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call   PR Newswire
Jul 7, 2021
04:01PM EDT  Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)   PR Newswire
Jun 28, 2021
05:17PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (Curis or the Company) (NASDAQ:CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jun 25, 2021
08:02AM EDT  Curis, Inc. To Join Russell 2000, 3000 And Microcap Indexes   Benzinga
08:01AM EDT  Curis, Inc. Set to Join Russell 2000(r), 3000(r) and Microcap(r) Indexes   PR Newswire
Jun 21, 2021
11:21AM EDT  Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity   Benzinga
Jun 20, 2021
01:53PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (Curis or the Company) (NASDAQ:CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jun 11, 2021
03:04PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 1%; Janux Therapeutics Shares Jump   Benzinga
12:02PM EDT  Mid-Day Market Update: Markets Mixed; Novan Shares Spike Higher   Benzinga
09:56AM EDT  Curis Shares Drop After Updated CA-4948 Data From Mid-Stage Blood Cancer Trial   Benzinga
08:05AM EDT  The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts   Benzinga
07:45AM EDT  Curis Announces Positive Updated Data From Phase 1/2 Study Of CA-4948 Monotherapy   RTTNews
07:03AM EDT  Curis Highlights Presentation Of Data From Ongoing Phase 1/2 Study Of CA-4948 At European Hematology Association 2021 Virtual Congress   Benzinga
07:01AM EDT  Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes   PR Newswire
Jun 4, 2021
08:07AM EDT  Curis To Host Virtual Event To Discuss Updated Clinical Data For CA-4948 In AML/MDS Presented At EHA   Benzinga
08:05AM EDT  Curis Reports Discussion Of Data From Phase 1/2 Study Of CA-4948 In Patients With AML And Myelodysplastic Syndromes   RTTNews
08:01AM EDT  Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in   PR Newswire
Jun 1, 2021
08:02AM EDT  Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint   PR Newswire
May 28, 2021
01:07PM EDT  Curis Option Alert: Jun 18 $17.5 Calls Sweep (31) near the Ask: 553 @ $1.0 vs 4394 OI; Ref=$14.53   Benzinga
May 25, 2021
08:03AM EDT  Curis to Present at Jefferies Virtual Healthcare Conference   PR Newswire
May 13, 2021
08:41AM EDT  Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates   Benzinga
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
04:05PM EDT  Curis Q1 EPS $(0.11) Misses $(0.09) Estimate, Sales $2.19M Miss $2.64M Estimate   Benzinga
04:03PM EDT  Curis Q1 Loss/share $0.11 Vs. Loss $0.28 Year Ago   RTTNews
04:01PM EDT  Curis Reports First Quarter 2021 Financial Results   PR Newswire
01:36PM EDT  Curis Inc. (CRIS), a biotechnology company focused on cancer treatment, Wednesday announced updated data from its ongoing phase 1/2 study of CA-4948 in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.   RTTNews
01:26PM EDT  UPDATE: Cantor Believes Data From Curis On Its IRAK1 Inhibitor Program Validates Rigel Pharma's Inhibitor Target, Says '...should be positive readthrough to RIGL's IRAK1/4 program, which is moving along...'   Benzinga
12:59PM EDT  Why Curis (CRIS) Shares Are Surging Today?   Benzinga
12:11PM EDT  Curis Shares Up 55%; Cantor Fitzgerald Issues Note Titled 'Updated AML data reiterates initial activity with CA-4948 (IRAK4)'   Benzinga
11:05AM EDT  Curis Reports Updated Data In Two Abstracts For CA-4948 Accepted For Presentation   RTTNews
11:05AM EDT  Curis Reports Updated Data In 2 Abstracts For CA-4948 Accepted For Presentation At European Hematology Association 2021 Virtual Congress   Benzinga
11:01AM EDT  Presentation at the European Hematology Association 2021 Virtual Congress   PR Newswire
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
04:22AM EDT  Earnings Scheduled For May 12, 2021   Benzinga
May 5, 2021
08:01AM EDT  Curis to Release First Quarter 2021 Financial Results and Hold Conference Call   PR Newswire
Apr 19, 2021
08:18AM EDT  Curis Inc. (CRIS) said Monday that it has received Orphan Drug designation from the U.S. Food and Drug Administration for CA-4948, a first-in-class, small molecule inhibitor of IRAK4 and Curis's most advanced therapeutic in clinical development.   RTTNews
08:02AM EDT  Curis Secures FDA Orphan Drug Designation For CA-4948 For Treatment Of AML And MDS   RTTNews
08:01AM EDT  Curis Receives FDA Orphan Drug Designation For CA-4948 For The Treatment Of AML and MDS   Benzinga
08:01AM EDT  Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML   PR Newswire
Apr 16, 2021
03:52PM EDT  Curis Shares Spike On Volume; Co. Granted Orphan Designation Status For Treatment Of Myelodysplastic Syndrome   Benzinga
Apr 7, 2021
04:01PM EDT  Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)   PR Newswire
Apr 6, 2021
08:03AM EDT  Curis to Present at 20th Annual Needham Virtual Healthcare Conference   PR Newswire
Mar 25, 2021
10:17AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2021   Benzinga
08:22AM EDT  B. Riley FBR Initiates Coverage On Curis with Buy Rating, Announces Price Target of $19   Benzinga
Mar 17, 2021
02:15PM EDT  Curis shares were trading lower after the company reported worse-than-expected Q4 EPS results.   Benzinga
09:05AM EDT  What's Happening With CRIS Stock, SRGA Stock And PDD Stock Wednesday?   Benzinga
Mar 16, 2021
04:24PM EDT  Recap: Curis Q4 Earnings   Benzinga
04:19PM EDT  Curis Q4 Loss/share $0.11 Vs. Loss $0.26 Year Ago   RTTNews
04:02PM EDT  Curis Q4 EPS $(0.11) Misses $(0.09) Estimate, Sales $3.04M Beat $2.84M Estimate   Benzinga
04:01PM EDT  Curis Reports Fourth Quarter and Year-End 2020 Financial Results   PR Newswire
08:17AM EDT  The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study   Benzinga
04:46AM EDT  Earnings Scheduled For March 16, 2021   Benzinga
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 10, 2021
04:32PM EST  Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting   Benzinga
04:31PM EST  Curis Announces Abstract for CA-4948 Accepted for Presentation at the American   PR Newswire
Mar 9, 2021
08:02AM EST  Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call   PR Newswire
Mar 2, 2021
08:01AM EST  Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference   PR Newswire
Feb 19, 2021
08:01AM EST  Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference   PR Newswire
Feb 9, 2021
08:38AM EST  Curis Inc. (CRIS) said that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed or refractory (R/R) hematologic malignancies. The initial data are expected in the fourth quarter of 2021.   RTTNews
08:10AM EST  Curis Reports First Patient Dosed In Phase 1 Study Of CA-4948 In Combo With Ibrutinib In Patients With Relapsed, Refractory Hematologic Malignancies   Benzinga
08:04AM EST  Curis Doses First Patient In Phase 1 Study Of CA-4948 With Ibrutinib In Patients With R/R Hematologic Malignancies   RTTNews
08:03AM EST  Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies   PR Newswire
Feb 2, 2021
08:46AM EST  Curis Inc. (CRIS) said Tuesday that it has initiated a phase 2 investigator-sponsored trial. The trial will evaluate CA-4948, a novel, small molecule IRAK4 kinase inhibitor, for the treatment of anemia in patients with very low, low, or intermediate-risk myelodysplastic syndromes or MDS.   RTTNews
08:07AM EST  Curis Reports Initiation Of Its Phase 2 LUCAS Study Of CA-4948 For Treatment Of Anemia   Benzinga
08:06AM EST  Curis Begins Phase 2 LUCAS Study Of CA-4948 For Anemia In Patients With Myelodysplastic Syndromes   RTTNews
08:01AM EST  CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes   PR Newswire
Jan 30, 2021
02:40PM EST  Robinhood Expands Trading Restrictions To 50 Stocks, Including GameStop, General Motors, Starbucks, Several SPACs   Benzinga
Jan 29, 2021
03:40PM EST  Robinhood Updates Limitations For Stock Trading   Benzinga
10:21AM EST  Mid-Morning Market Update: Markets Open Lower; Caterpillar Earnings Top Expectations   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 15, 2021
10:49AM EST  Curis shares were trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $9 to $16.   Benzinga
08:18AM EST  10 Biggest Price Target Changes For Friday   Benzinga
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
06:06AM EST  HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $16   Benzinga
Jan 14, 2021
08:03AM EST  Curis to Present at B. Riley Securities Virtual Oncology Investor Conference   PR Newswire
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 8, 2021
04:01PM EST  Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)   PR Newswire
Jan 6, 2021
07:31AM EST  The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping   Benzinga
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
08:01AM EST  Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference   PR Newswire
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 22, 2020
04:05PM EST  CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors   GlobeNewswire Inc
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
09:37AM EST  Learning Caution In A Volatile December   Benzinga
08:09AM EST  Curis Says Closes Underwritten Public Offering Of 29.5 Mln Shares With $169.6 Mln In Gross Proceeds   RTTNews
08:02AM EST  in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares   PR Newswire
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 9, 2020
10:18AM EST  Stock Alert: Curis Shares Gain After Pricing Of Public   RTTNews
09:32AM EST  Curis Prices Public Offering Of 25.65 Mln Shares At $5.75 Per Share   RTTNews
09:31AM EST  Curis Prices 25.65M Shares $5.75/Share   Benzinga
09:30AM EST  Curis Announces Pricing of Public Offering of Common Stock   PR Newswire
Dec 8, 2020
04:14PM EST  Curis Announces Proposed Public Offering Of Common Stock; Terms Not Disclosed   Benzinga
04:14PM EST  Curis Announces Proposed Public Offering of Common Stock   PR Newswire
02:31PM EST  Mid-Afternoon Market Update: Dow Jumps 150 Points; Stitch Fix Shares Gain On Upbeat Q1 Earnings   Benzinga
12:28PM EST  Mid-Day Market Update: US Stocks Turn Positive; Arcturus Therapeutics Shares Plunge   Benzinga
10:36AM EST  HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $9   Benzinga
10:34AM EST  HC Wainwright Raises Price Target On Curis From $5 To $9, Reiterates Buy   Benzinga
10:19AM EST  Shares of Curis, Inc. (CRIS) skyrocketed more than five-fold on Tuesday morning after the biotechnology company focused on cancer treatment reported positive leukemia treatment trial results.   RTTNews
10:16AM EST  Mid-Morning Market Update: Markets Edge Lower; AutoZone Earnings Top Estimates   Benzinga
09:50AM EST  Return On Capital Employed Overview: Curis   Benzinga
07:08AM EST  Curis Reports Positive Preliminary Data From Phase 1 Study Of CA-4948 Monotherapy In Patients With AML Or High-risk MDS   RTTNews
07:06AM EST  Curis Announces Preliminary Data From Ongoing Phase 1 Study Of CA-4948 Monotherapy In Patients With Relapsed Or Refractory Acute Myeloid Leukemia And Myelodysplastic Syndromes   Benzinga
07:01AM EST  Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes   PR Newswire
Dec 7, 2020
01:32PM EST  Curis Announces Updated Preliminary Data From Ongoing Phase 1 Study Of CA-4948 Showing Durable, Dose-Dependent Reductions In Tumor Burden In Patients With Relapsed Or Refractory Non-Hodgekin's Lymphoma   Benzinga
01:30PM EST  Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma   PR Newswire
Dec 6, 2020
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 2, 2020
08:43AM EST  Curis To Discuss CA-4948 Clinical Data On Non-Hodgkin Lymphoma, Acute Myeloid Leukemia   RTTNews
08:41AM EST  Curis to Host Virtual Event to Discuss CA-4948 Clinical Data   PR Newswire
Nov 24, 2020
09:51AM EST  Benzinga's Top Upgrades, Downgrades For November 24, 2020   Benzinga
06:33AM EST  HC Wainwright & Co. Initiates Coverage On Curis with Buy Rating, Announces Price Target of $5   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
05:02PM EST  Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent   Benzinga
04:54PM EST  Curis: Q3 Earnings Insights   Benzinga
04:14PM EST  Curis Q3 EPS $(0.11) Beats $(0.13) Estimate, Sales $2.74M Beat $2.57M Estimate   Benzinga
04:07PM EST  Curis Q3 Loss/Shr $0.11 Vs Loss $0.19 Prior Year   RTTNews
04:06PM EST  Curis Reports Third Quarter 2020 Financial Results   PR Newswire
04:01PM EST  Curis Announces Collaboration with the National Cancer Institute for the   PR Newswire
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 4, 2020
01:31PM EST  Curis Announces Three Abstracts For CA-4948 Accepted For Presentation At 62nd American Society Of Hematology Annual Meeting And Exposition   Benzinga
01:30PM EST  Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the   PR Newswire
08:01AM EST  Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference   PR Newswire
Nov 2, 2020
04:02PM EST  Curis to Release Third Quarter 2020 Financial Results and Hold Conference Call   PR Newswire
Oct 21, 2020
08:08AM EDT  Curis Highlights Publication In ACS Medicinal Chemistry Letters Showcasing Targeted Potency And Ideal Pharmacologic Properties Of CA-4948 For Treatment Of Hematologic Malignancies   Benzinga
08:07AM EDT  Curis Highlights Publication In ACS Medicinal Chemistry Letters Showcasing Ideal Pharmacologic Properties Of CA-4948   RTTNews
08:02AM EDT  Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies   PR Newswire
Oct 14, 2020
05:03PM EDT  Curis Reports Trial In Progress Abstract For CI-8993 Monoclonal Anti-VISTA Antibody Accepted For Poster Presentation At Society For Immunotherapy Of Cancer Meeting Nov. 14   Benzinga
05:01PM EDT  Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society   PR Newswire
Sep 10, 2020
04:01PM EDT  Curis to Present at Upcoming Investor Conferences   PR Newswire
Aug 4, 2020
04:14PM EDT  Curis Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $2.36M Miss $2.55M Estimate   Benzinga
04:03PM EDT  Curis Q2 Net Loss $6.7 Mln Or $0.17/Shr Vs Net Loss $7.2 Mln Or $0.22/Shr Last Year   RTTNews
04:02PM EDT  Curis Reports Second Quarter 2020 Financial Results   PR Newswire
05:19AM EDT  Earnings Scheduled For August 4, 2020   Benzinga
Jul 28, 2020
08:01AM EDT  Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call   PR Newswire
Jul 17, 2020
09:50AM EDT  Benzinga's Top Upgrades, Downgrades For July 17, 2020   Benzinga
06:24AM EDT  Cantor Fitzgerald Initiates Coverage On Curis with Overweight Rating, Announces Price Target of $4   Benzinga
Jul 16, 2020
04:54PM EDT  Hearing Cantor Fitzgerald Initiated Coverage On Curis With Overweight Rating And $4 Price Target; Unconfirmed   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC